US Stock MarketDetailed Quotes
SCPH scPharmaceuticals
- 3.710
- +0.090+2.49%
Close Dec 2 16:00 ET
- 3.750
- +0.040+1.08%
Post 20:01 ET
185.65MMarket Cap-1902P/E (TTM)
3.770High3.530Low453.65KVolume3.630Open3.620Pre Close1.67MTurnover1.70%Turnover RatioLossP/E (Static)50.04MShares6.71052wk High6.04P/B99.30MFloat Cap3.07552wk Low--Dividend TTM26.77MShs Float18.170Historical High--Div YieldTTM6.63%Amplitude2.440Historical Low3.690Avg Price1Lot Size
scPharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -29.54%-17.42M | -43.04%-20.23M | -7.32%-17.7M | -71.34%-59.24M | -28.06%-15.16M | -64.12%-13.45M | -97.09%-14.14M | -123.83%-16.49M | -27.35%-34.58M | -66.77%-11.84M |
| Net income from continuing operations | -124.54%-35.11M | -20.74%-17.09M | -25.85%-14.11M | -48.79%-54.81M | -49.35%-13.81M | -53.85%-15.63M | -45.96%-14.15M | -45.00%-11.21M | -31.40%-36.84M | -26.37%-9.25M |
| Operating gains losses | 30,986.11%11.19M | 555.97%1.11M | -210.23%-3.12M | -173.33%-3.65M | ---2.44M | --36K | ---243K | ---1.01M | ---1.34M | ---- |
| Depreciation and amortization | 55.61%-87K | -52.29%52K | -51.43%51K | 33.76%626K | 406.67%608K | -266.10%-196K | -14.84%109K | 2.94%105K | 6.85%468K | 8.11%120K |
| Other non cash items | 1,611.63%9.57M | 23.85%649K | 24.95%616K | 145.02%2.17M | 2.61%590K | 514.29%559K | 403.85%524K | 332.46%493K | 59.57%884K | 299.31%575K |
| Change In working capital | -687.60%-4.31M | -437.60%-6.46M | 53.52%-2.48M | -1,706.00%-6.32M | 79.25%-515K | -25.71%734K | -173.38%-1.2M | -980.57%-5.34M | 86.53%-350K | -267.16%-2.48M |
| -Change in receivables | -20.90%-3.1M | -124.68%-344K | 57.29%-1.28M | ---4.49M | ---314K | ---2.57M | --1.39M | ---3M | --0 | --0 |
| -Change in inventory | -118.75%-2.82M | -160.44%-5.76M | 68.28%-758K | -518.62%-7.61M | -39.51%-1.72M | ---1.29M | ---2.21M | ---2.39M | ---1.23M | ---1.23M |
| -Change in prepaid assets | -272.26%-708K | -227.89%-917K | 261.69%422K | 124.92%221K | 61.80%-646K | 8,320.00%411K | 15.27%717K | -239.57%-261K | -279.06%-887K | -43.91%-1.69M |
| -Change in payables and accrued expense | -44.48%2.32M | 150.86%560K | -371.92%-862K | 214.43%5.56M | 392.26%2.16M | 320.85%4.18M | -208.37%-1.1M | 146.55%317K | 174.71%1.77M | -12.02%439K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -29.54%-17.42M | -43.04%-20.23M | -7.32%-17.7M | -71.34%-59.24M | -28.06%-15.16M | -64.12%-13.45M | -97.09%-14.14M | -123.83%-16.49M | -27.35%-34.58M | -66.77%-11.84M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | 99.96%-9K | -99.99%1K | 318.84%29.32M | 143.54%19.97M | 161.55%26.46M | -312.58%-22.93M | 1,194.89%9.43M | 154.73%7M | -242.73%-45.86M | -1,055.17%-42.99M |
| Net PPE purchase and sale | ---9K | ---- | ---- | -90.48%-40K | ---37K | --0 | ---- | ---- | -133.33%-21K | --0 |
| Net investment purchase and sale | --0 | -99.99%1K | 318.84%29.32M | 143.64%20.01M | 161.64%26.5M | -312.29%-22.93M | 1,195.24%9.43M | 154.76%7M | -242.62%-45.84M | -1,055.38%-42.99M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | 99.96%-9K | -99.99%1K | 318.84%29.32M | 143.54%19.97M | 161.55%26.46M | -312.58%-22.93M | 1,194.89%9.43M | 154.73%7M | -242.73%-45.86M | -1,055.17%-42.99M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 103,448.53%70.41M | -53.68%283K | -99.89%15K | -80.77%14.85M | -99.45%467K | 102.75%68K | 125.29%611K | 652.80%13.7M | 3,152.53%77.23M | 3,541.86%84.6M |
| Net issuance payments of debt | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- | 1,292.04%29.8M | 1,592.04%37.3M |
| Net common stock issuance | --53.55M | --0 | --0 | -70.61%14.04M | --0 | --0 | --334K | --13.7M | --47.77M | --47.77M |
| Proceeds from stock option exercised by employees | -30.88%47K | 2.17%283K | --15K | 274.19%812K | 424.72%467K | 195.65%68K | 229.76%277K | --0 | 325.49%217K | -27.64%89K |
| Net other financing activities | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- | -583.95%-554K | ---- |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 103,448.53%70.41M | -53.68%283K | -99.89%15K | -80.77%14.85M | -99.45%467K | 102.75%68K | 125.29%611K | 652.80%13.7M | 3,152.53%77.23M | 3,541.86%84.6M |
| Net cash flow | ||||||||||
| Beginning cash position | -46.04%38.5M | -22.54%58.45M | -34.29%46.81M | -4.31%71.24M | -15.50%35.04M | 72.51%71.35M | 45.63%75.45M | -4.31%71.24M | 3.40%74.45M | -47.84%41.47M |
| Current changes in cash | 245.92%52.98M | -386.06%-19.94M | 176.32%11.63M | -661.74%-24.43M | -60.46%11.77M | -32,809.91%-36.31M | 60.74%-4.1M | 118.60%4.21M | -230.95%-3.21M | 688.96%29.77M |
| End cash Position | 161.07%91.48M | -46.04%38.5M | -22.54%58.45M | -34.29%46.81M | -34.29%46.81M | -15.50%35.04M | 72.51%71.35M | 45.63%75.45M | -4.31%71.24M | -4.31%71.24M |
| Free cash flow | -29.60%-17.43M | -43.01%-20.23M | -7.32%-17.7M | -71.35%-59.28M | -28.37%-15.2M | -63.82%-13.45M | -97.13%-14.14M | -123.65%-16.49M | -27.39%-34.6M | -66.79%-11.84M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data